Merck & Co. (MRK)
(Delayed Data from NYSE)
$114.73 USD
-0.23 (-0.20%)
Updated Sep 25, 2024 04:00 PM ET
After-Market: $114.81 +0.08 (0.07%) 7:58 PM ET
4-Sell of 5 4
C Value C Growth A Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$114.73 USD
-0.23 (-0.20%)
Updated Sep 25, 2024 04:00 PM ET
After-Market: $114.81 +0.08 (0.07%) 7:58 PM ET
4-Sell of 5 4
C Value C Growth A Momentum B VGM
Zacks News
AZN Stock Slips as Dato-DXd Cancer Study Misses Survival Goal
by Zacks Equity Research
AZN's Daiichi Sankyo-partnered datopotamab deruxtecan fails to show overall survival benefits in a breast cancer study. Stock falls.
Company News for Sep 24, 2024
by Zacks Equity Research
Companies in The News Are: TSLA, DPZ, INTC, APO, MRK
EMA Committee Endorses AbbVie's Elahere in Ovarian Cancer
by Zacks Equity Research
If approved, this will be the first regulatory approval for ABBV's Elahere in the European Union.
MRK Gets Positive CHMP Nod for Keytruda in Two Gynecologic Cancers
by Zacks Equity Research
The Committee for Medicinal Products for Human Use recommends marketing approval for Merck's Keytruda for treating two types of gynecologic cancers.
Merck (MRK) Stock Moves -0.05%: What You Should Know
by Zacks Equity Research
Merck (MRK) reachead $117.17 at the closing of the latest trading day, reflecting a -0.05% change compared to its last close.
Pharma Stock Roundup: FDA Approvals for LLY, MRK, AZN & JNJ Drugs
by Kinjel Shah
FDA approves Lilly's eczema drug, Ebglyss, and the expanded use of Novartis' Kisqali, Merck's Keytruda and AstraZeneca's Fasenra.
Merck Loses Around $32B in 3 Months: Time to Sell the Stock?
by Kinjel Shah
Declining estimates and the recent price drop make investors skeptical about holding MRK stock.
Merck (MRK) Stock Dips While Market Gains: Key Facts
by Zacks Equity Research
In the closing of the recent trading day, Merck (MRK) stood at $117.23, denoting a -1.19% change from the preceding trading day.
Merck's Keytruda Obtains its First FDA Approval for Mesothelioma
by Zacks Equity Research
The FDA approves MRK's Keytruda for first-line treatment of malignant pleural mesothelioma. This marks Keytruda's first approval for the given indication.
Investors Heavily Search Merck & Co., Inc. (MRK): Here is What You Need to Know
by Zacks Equity Research
Merck (MRK) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Study: Merck and Daiichi's Lung Cancer Treatment Shows Promise
by Zacks Equity Research
MRK and Daiichi Sankyo's patritumab deruxtecan shows statistically significant progression-free survival improvement in previously treated EGFR-mutated NSCLC.
Is It Worth Investing in Merck (MRK) Based on Wall Street's Bullish Views?
by Zacks Equity Research
According to the average brokerage recommendation (ABR), one should invest in Merck (MRK). It is debatable whether this highly sought-after metric is effective because Wall Street analysts' recommendations tend to be overly optimistic. Would it be worth investing in the stock?
NuCana Stock Soars 151% on Upbeat Efficacy Data From Melanoma Study
by Zacks Equity Research
NCNA stock surges 151% on positive efficacy data from the mid-stage melanoma study of NUC-7738 in combination with Merck's Keytruda.
Instil Bio Stock Skyrockets 641% in One Week: Here's Why
by Zacks Equity Research
A rival posted encouraging data on a drug that outperformed Keytruda in certain NSCLC patients. TIL licenses a drug candidate that uses a similar mechanism.
Merck (MRK) Increases Yet Falls Behind Market: What Investors Need to Know
by Zacks Equity Research
In the most recent trading session, Merck (MRK) closed at $115.86, indicating a +0.53% shift from the previous trading day.
MRNA Stock Falls 12% on Lowered Sales Outlook, R&D Budget Cuts
by Zacks Equity Research
As part of its strategic prioritization, Moderna aims to cut its R&D expenses by 20% over the next four years. It decides to end five pipeline programs to save costs.
Here's Why Merck (MRK) Gained But Lagged the Market Today
by Zacks Equity Research
Merck (MRK) closed at $115.25 in the latest trading session, marking a +0.47% move from the prior day.
Bristol Myers Stock Rises 16% in 3 Months: Buy, Sell or Hold?
by Zacks Equity Research
BMY's recent rally gives investors a ray of hope after the downturn earlier on in 2024. However, we advise investors not to be over-optimistic at this point and look before they leap.
Corvus Stock Up on Initiation of Phase III Lymphoma Study on Lead Drug
by Zacks Equity Research
CRVS stock gains 14% on initiating a registrational study on its lead candidate, soquelitinib, to treat relapsed/refractory peripheral T-cell lymphoma.
Summit Hits Record High on Lung Cancer Drug Topping Merck's Keytruda
by Zacks Equity Research
Data from a late-stage study shows that SMMT's experimental antibody beat Keytruda in a head-to-head setting in treating certain patients with NSCLC.
MRK Stock Dips After SMMT's Cancer Drug Outshines Keytruda in Study
by Zacks Equity Research
Merck's Keytruda is the standard of care for NSCLC. Ivonescimab, however, shows clinically meaningful benefit over Keytruda in a phase III study in NSCLC.
Merck (MRK) is a Top Dividend Stock Right Now: Should You Buy?
by Zacks Equity Research
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Merck (MRK) have what it takes? Let's find out.
Merck (MRK) Stock Moves -0.63%: What You Should Know
by Zacks Equity Research
Merck (MRK) closed the most recent trading day at $117.84, moving -0.63% from the previous trading session.
Pharma Stock Roundup: EU Nod for Expanded Use of MRK's Keytruda & More
by Kinjel Shah
European Commission approves expanded use of Merck's Keytruda in bladder cancer. Sanofi & Lilly announce data from phase III studies on pipeline candidates.
Merck Starts Late-Stage Study on Recently Acquired Ophthalmology Drug
by Zacks Equity Research
The clinical study will evaluate MRK's experimental antibody treatment in patients with diabetic macular edema, a major cause of vision loss.